Sumitomo Pharma Co Ltd
TSE:4506

Watchlist Manager
Sumitomo Pharma Co Ltd Logo
Sumitomo Pharma Co Ltd
TSE:4506
Watchlist
Price: 2 750 JPY -3.17% Market Closed
Market Cap: 1.1T JPY

Relative Value

The Relative Value of one Sumitomo Pharma Co Ltd stock under the Base Case scenario is 1 323.42 JPY. Compared to the current market price of 2 750 JPY, Sumitomo Pharma Co Ltd is Overvalued by 52%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
1 323.42 JPY
Overvaluation 52%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
75
Median 3Y
0.6
Median 5Y
0.7
Industry
2.7
Forward
2.6
vs History
44
vs Industry
Median 3Y
-0.8
Median 5Y
5.3
Industry
21.6
Forward
12.6
vs History
4
vs Industry
26
Median 3Y
-0.5
Median 5Y
5.5
Industry
16.9
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-1.1
Industry
22.9
vs History
0
vs Industry
43
Median 3Y
1
Median 5Y
1
Industry
2.3
vs History
0
vs Industry
75
Median 3Y
0.9
Median 5Y
0.9
Industry
3
Forward
3.1
vs History
0
vs Industry
78
Median 3Y
1.4
Median 5Y
1.4
Industry
5.6
vs History
12
vs Industry
5
Median 3Y
-1.1
Median 5Y
4.6
Industry
13.4
Forward
10.5
vs History
22
vs Industry
Median 3Y
-0.9
Median 5Y
7.5
Industry
16.7
Forward
49.1
vs History
7
vs Industry
13
Median 3Y
-1.1
Median 5Y
5.8
Industry
16.1
vs History
0
vs Industry
Median 3Y
-1.7
Median 5Y
5
Industry
18.9
vs History
0
vs Industry
76
Median 3Y
0.4
Median 5Y
0.5
Industry
2

Multiples Across Competitors

Competitors Multiples
Sumitomo Pharma Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Sumitomo Pharma Co Ltd
TSE:4506
1.1T JPY 2.5 7.1 8.6 10
US
Eli Lilly and Co
NYSE:LLY
978B USD 16.5 53.3 35.7 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.9B USD 5.7 21.1 17.2 22.3
CH
Roche Holding AG
SIX:ROG
276.1B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
217.5B GBP 5 30.9 108.3 158.5
CH
Novartis AG
SIX:NOVN
220.2B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
271.7B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
JP
Sumitomo Pharma Co Ltd
TSE:4506
Average P/E: 22.9
7.1
50%
0.1
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
21.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.9
37%
0.8
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Sumitomo Pharma Co Ltd
TSE:4506
Average EV/EBITDA: 400.8
8.6
41%
0.2
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Sumitomo Pharma Co Ltd
TSE:4506
Average EV/EBIT: 1 713.3
10
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5